SUTENT is an inhibitor of multiple receptor tyrosine kinases (TKIs), including the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), which are expressed in many types of solid tumours and are thought to play a crucial role in angiogenesis.¹

Dysregulation of the VEGF pathway is frequently associated with RCC, due to loss of function of the von Hippel-Lindau gene² making mRCC a highly vascular tumour and underlying why the VEGF pathway continues to be a target in RCC.²

In 2006:

• SUTENT was approved for first-line mRCC, transforming the treatment landscape and pushing OS to over 2 years for the first time in the history of the disease^3,4,9

Today:

• SUTENT remains a standard of care in first-line mRCC¹⁰
• Over 300,000 patients have been treated with SUTENT worldwide¹¹
• Real-world experience has demonstrated OS of over 30 months⁸

Motzer RJ, et al. Lancet Oncol 2019;20:1370–1385
Gore ME, et al. Br J Cancer 2015;113:12–19
Noize P, et al. Pharmacoepidemiol Drug Saf 2017;26:1561–1569.
Ruiz-Morales J, et al. Eur J Cancer 2016;65:102–108.
Lalani A, et al. Can Urol Assoc J 2017;11:112–117.
Motzer RJ, et al. J Clin Oncol 2009;27:3584–3590.
Motzer RJ, et al. N Engl J Med 2013;369:722–731.

Motzer RJ, et al. 2009. 
Gore ME, et al. 2015. 
Ruiz-Morales JM, et al. 2016.
Noize P, et al. 2017. 
Lalani AA, et al. 2017.

Data taken from Motzer RJ, et al. 2009. Gore ME, et al. 2015. Ruiz-Morales JM, et al. 2016. Noize P, et al. 2017. Lalani AA, et al. 2017.

EAP, Expanded Access Programme. IMDC, International Metastatic Renal Cell Carcinoma Database Consortium. OS, overall survival. No cross-trial comparisons may be made since trials were conducted using different methodologies and at different time points. Final and investigator review analyses unless otherwise stated.​​​​​​​

*Clinical trial data.^†Data for MSKCC risk groups. ^‡Data for IMDC risk groups